AbCellera Biologics Q3 EPS $(0.10) Beats $(0.13) Estimate, Sales $6.60M Miss $11.90M Estimate
Author: Benzinga Newsdesk | November 02, 2023 04:25pm
AbCellera Biologics (NASDAQ:
ABCL) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 225 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $6.60 million which missed the analyst consensus estimate of $11.90 million by 44.55 percent. This is a 93.49 percent decrease over sales of $101.38 million the same period last year.
Posted In: ABCL